Get the Stockscreener App
9.52
3.82%
0.35
Cel-Sci Corp. stock is traded at $9.52, with a volume of 152.15K.
It is up +3.82% in the last 24 hours and up +80.65% over the past month.
CEL-SCI Corporation engages in the research and development of drugs and vaccines. Its lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. The company's Multikine is also used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.
See More
Previous Close:
$9.17
Open:
$9.29
24h Volume:
152.15K
Relative Volume:
0.19
Market Cap:
$65.52M
Revenue:
-
Net Income/Loss:
$-26.92M
P/E Ratio:
-18.67
EPS:
-0.51
Net Cash Flow:
$-18.92M
1W Performance:
+9.43%
1M Performance:
+80.65%
6M Performance:
-19.87%
1Y Performance:
-71.41%
1-Day Range:
$9.12
$9.86
1-Week Range:
$8.04
$9.86
52-Week Range:
$1.98
$39.30
Cel-Sci Corp. Stock (CVM) Company Profile
Name
Cel-Sci Corp.
Sector
Industry
Phone
703-506-9460
Address
8229 Boone Boulevard, Suite 802, Vienna, VA
Compare CVM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVM
Cel-Sci Corp.
|
9.52 | 61.39M | 0 | -26.92M | -18.92M | -0.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Cel-Sci Corp. Stock (CVM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-02-15 | Initiated | Dawson James | Buy |
Cel-Sci Corp. Stock (CVM) Latest News
Is CEL SCI Corporation showing signs of accumulation2025 Trading Recap & Growth Oriented Trade Recommendations - Newser
Forecasting CEL SCI Corporation price range with options dataJuly 2025 Setups & AI Powered Market Entry Ideas - Newser
Should you hold or exit CEL SCI Corporation now2025 Geopolitical Influence & Free Technical Pattern Based Buy Signals - Newser
Will CEL SCI Corporation continue its uptrendBuy Signal & Safe Capital Investment Plans - Newser
Order flow analysis tools used on CEL SCI CorporationWeekly Trend Recap & Daily Oversold Bounce Ideas - Newser
What MACD and RSI say about CEL SCI CorporationGap Up & High Accuracy Investment Signals - Newser
CEL SCI Corporation stock trendline breakdownJuly 2025 WrapUp & Daily Volume Surge Trade Alerts - Newser
Published on: 2025-08-17 13:30:33 - newsyoung.net
Published on: 2025-08-17 09:16:10 - newsyoung.net
What to do if you’re stuck in CEL SCI CorporationGDP Growth & AI Forecast Swing Trade Picks - Newser
What high frequency data says about CEL SCI CorporationJuly 2025 Catalysts & Fast Exit Strategy with Risk Control - Newser
Has CEL SCI Corporation found a price floorProfit Target & AI Forecasted Stock Moves - Newser
Applying sector rotation models to CEL SCI CorporationWeekly Market Report & Safe Capital Growth Tips - Newser
Is CEL SCI Corporation stock entering bullish territoryJuly 2025 Reactions & Daily Profit Focused Screening - Newser
Cel-Sci: Fiscal Q3 Earnings Snapshot - Norwalk Hour
Will CEL SCI Corporation bounce back from current supportEarnings Miss & Daily Profit Focused Stock Screening - Newser
CEL-SCI's Cancer Drug Could Hit Saudi Market in 60 Days as Partnership Deal Nears - Stock Titan
Saudi pharma company files breakthrough designation for Multikine By Investing.com - Investing.com Canada
Cancer Drug That Doubles Survival Rate Nears Quick Approval in Saudi Arabia - Stock Titan
Cel-Sci Corp (AMEX: CVM) Is Up 8.53% – Is It Capable Of A Rally? - stocksregister.com
Using Ichimoku Cloud for CEL SCI Corporation technicalsMarket Growth Review & Low Drawdown Investment Ideas - Newser
What makes CEL SCI Corporation stock price move sharplyAccurate Forecast System with AI Support - Newser
Comparing CEL SCI Corporation in custom built stock radarsFree Stock Portfolio Allocation Guidance - Newser
Visualizing CEL SCI Corporation stock with heatmaps7-Day Equity Return Range Forecast Model - Newser
Will earnings trigger a reversal in CEL SCI CorporationEntry Opportunity Screener with Confirmation - Newser
Can momentum traders help lift CEL SCI CorporationWeekly Entry Signal Based Forecast Tool - Newser
How high can CEL SCI Corporation stock goFree Trend Analysis for Safer Trades - Newser
How institutional ownership impacts CEL SCI Corporation stockWeekly Stock Movement Prediction Watchlist - Newser
Custom strategy builders for tracking CEL SCI CorporationShort-Term Upside Breakout Forecast System - Newser
Is CEL SCI Corporation stock poised for growthFree Daily Volume Spike Trading Signals - Newser
Does CEL SCI Corporation fit your quant trading modelEntry Zone Forecast for Momentum Trading - Newser
CEL SCI Corporation Nearing Breakout Level After BounceWeekly Growth Stock Entry Point Alerts Highlighted - beatles.ru
Is CEL SCI Corporation a good long term investmentAchieve breakthrough financial results today - Jammu Links News
What moving averages say about CEL SCI CorporationChart-Based Entry Confirmation for Beginners - newser.com
SRCE names Andrea G. Short CEO; founder shifts to Executive Chairman | CVM SEC FilingForm 4 - Stock Titan
How did CVM's operating expenses trend in Q1 2025? - AInvest
Cel-Sci Corp. Stock (CVM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):